Gimistotug Biosimilar - Research Grade

Human

TNFRSF4

>1mg/ml

IgG1 - kappa

CHO Cells

Ivuxolimab Biosimilar - Research Grade (ICH5119), Cudarolimab Biosimilar - Research Grade (ICH5458), Revdofilimab Biosimilar - Research Grade (ICH5818), Rocatinlimab Biosimilar - Research Grade (ICH5828), Tavolimab Biosimilar - Research Grade (ICH5903), Telazorlimab Biosimilar - Research Grade (ICH5909), Vonlerolizumab Biosimilar - Research Grade (ICH5989)

https://www.imgt.org/mAb-DB/

ICH3002

P43489

Blue ice

This product is a research-grade, unconjugated recombinant analog of the anti-OX40 (TNFRSF4/CD134) antibody Gimistotug (originator development code BGB-A445), a human IgG1-kappa immunoglobulin. It is supplied strictly for research use only and is not the clinical therapeutic; it is not intended for human or veterinary use. Built around the OX40 target, this non-therapeutic biosimilar reproduces the antigen-binding specificity of the originator and is useful as a defined, reproducible reagent for in-vitro and preclinical work: as a positive control in binding and epitope-competition assays, a benchmark for characterizing biosimilar or novel anti-OX40 candidates, a tool for probing OX40/OX40L costimulatory signaling, and a reference standard in ADCC or antibody-engineering studies. The IgG1-kappa framework supports Fc-dependent effector-function experiments. It is offered at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg options), and in bulk milligram-to-gram quantities suitable for assay development, scale-up, and preclinical model work where lot consistency and material quantity matter. OX40 (TNFRSF4, CD134; UniProt P43489) is a type I transmembrane glycoprotein of the tumor necrosis factor receptor superfamily and a costimulatory receptor for T cells. It is not constitutively expressed but is induced on activated CD4+ and, at lower levels, CD8+ T cells roughly 24-72 hours after T-cell receptor engagement; it is also found on some regulatory T cells, NK, NK-T cells and neutrophils. Its ligand, OX40L (TNFSF4/CD252), is expressed on activated antigen-presenting cells such as dendritic cells, macrophages and B cells. OX40 engagement delivers a late costimulatory signal that recruits TRAF adaptors, activates NF-kB and NFAT pathways, and enhances T-cell proliferation, survival, cytokine production (including IL-2) and effector differentiation while modulating regulatory T-cell activity. Because of this role in amplifying antigen-primed T-cell responses, OX40 is a target of interest in tumor immunology and immune-modulation research.

ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, Tumor necrosis factor receptor superfamily member 4, TXGP1L

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks